# Daewon Pharmaceutical Co., Ltd. clinical trials: 49 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 49 trials with Daewon Pharmaceutical Co., Ltd. as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Daewon Pharmaceutical Co., Ltd.: 49 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/daewon-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931521 | Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux Disease | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Completed | Erosive Reflux Disease, GERD (Gastroesophageal Reflux Disease) | 328 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931521) |
| July 8, 2026 | NCT07691242 | Multiple Ascending Dose Study of DW4421 | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Adult Volunteers | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691242) |
| March 3, 2026 | NCT07444762 | Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Completed | Primary Hypercholesterolemia, Mixed Dyslipidemia | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444762) |
| February 3, 2026 | NCT07382661 | Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Adult Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07382661) |
| January 23, 2026 | NCT07364877 | A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Enrolling by invitation | Healthy Adult Volunteer | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364877) |
| January 23, 2026 | NCT07364851 | A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Adult Volunteer | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364851) |
| January 23, 2026 | NCT07364838 | Study to Evaluate the Effect of Food on the Pharmacokinetics and Pharmacodynamics Characteristics in Healthy Adult Volunteers | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Completed | GERD (Gastroesophageal Reflux Disease) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364838) |
| January 20, 2026 | NCT07349589 | Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Adult | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349589) |
| January 15, 2026 | NCT07343245 | A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Healthy Adult | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07343245) |
| January 6, 2026 | NCT07319559 | Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy... | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Completed | Mixed Dyslipidemia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07319559) |
| January 6, 2026 | NCT07319520 | Clinical Trial to Evaluate the Efficacy and Safety of DW4902 | Daewon Pharmaceutical Co., Ltd. | Phase 2 | Completed | Myoma of Uterus | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07319520) |
| September 11, 2025 | NCT07168473 | Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Perennial Allergic Rhinitis Accompanied by Asthma | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168473) |
| July 30, 2025 | NCT07093697 | A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212 | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Completed | Acute Bronchitis | 273 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07093697) |
| July 21, 2025 | NCT07076056 | Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Completed | Type 2 Diabetes | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07076056) |
| November 28, 2023 | NCT06147908 | Clinical Trial to Evaluate the Pharmacokinetic Characteristics of DW5221 and DW5221-R | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Completed | Apetite Stimulants | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06147908) |
| August 1, 2023 | NCT05970679 | Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Completed | Hypercholesterolemia, Dyslipidemia | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05970679) |
| January 13, 2023 | NCT05683951 | Clinical Trial to Evaluate the Efficacy and Safety of DWKH | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Completed | Respiratory Infection | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05683951) |
| January 31, 2022 | NCT05214690 | A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2 | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Completed | Osteoarthritis, Rheumatoid Arthritis, Back Pain, Acute Upper Respiratory Tract Infection | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05214690) |
| January 31, 2022 | NCT05214677 | A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809 | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Completed | Osteoarthritis, Rheumatoid Arthritis, Back Pain, Acute Upper Respiratory Tract Infection | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05214677) |
| December 20, 2021 | NCT05163756 | To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Completed | Gastritis Acute, Gastritis Chronic | 332 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05163756) |
| December 13, 2021 | NCT05155072 | Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903 | Daewon Pharmaceutical Co., Ltd. | Phase 1 | Completed | Gastritis | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05155072) |
| September 9, 2020 | NCT04541134 | Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Primary Dysmenorrhea | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04541134) |
| February 7, 2020 | NCT04260555 | Clinical Trial to Evaluate the Efficacy and Safety of 'DW1601' in Acute Bronchitis | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Acute Bronchitis | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04260555) |
| March 14, 2019 | NCT03874260 | Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately... | Daewon Pharmaceutical Co., Ltd. | Phase 4 | Unknown | Dyslipidemias | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03874260) |
| March 14, 2019 | NCT03874247 | Clinical Trial to Evaluate the Efficacy and Safety of 'Pelubiprofen Controlled Released Tab.' in Acute Traumatic Injury | Daewon Pharmaceutical Co., Ltd. | Phase 3 | Unknown | Acute Traumatic Injury | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03874247) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 20 |
| Phase 2 | 4 |
| Phase 3 | 20 |
| Phase 4 | 4 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Unknown | 7 |
| Not yet recruiting | 4 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dyslipidemias | 4 |
| Hypercholesterolemia | 3 |
| Arthritis, Rheumatoid | 3 |
| Hypertension | 2 |
| Bronchitis | 2 |
| Kidney Failure, Chronic | 2 |
| Osteoarthritis | 2 |
| Back Pain | 2 |
| Gastroesophageal Reflux | 2 |
| Respiratory Tract Infections | 2 |
| Diabetes Mellitus, Type 2 | 1 |
| Fever | 1 |
| Osteoarthritis, Knee | 1 |
| Gastritis | 1 |
| Low Back Pain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Natural gas utilities in the United States](https://specstream.ai/data/businesses/natural-gas-utilities/united-states)
- [Estate planning law firms in the United States](https://specstream.ai/data/businesses/estate-planning-law-firms/united-states)
- [B2B advertising and marketing companies in the United States](https://specstream.ai/data/businesses/b2b-advertising-and-marketing-companies/united-states)
- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [Indonesian restaurants in the United States](https://specstream.ai/data/businesses/indonesian-restaurants/united-states)
